Novo Nordisk Shares Plunge on Weak 2026 Guidance, Eye Support at $36.80
Novo Nordisk’s stock fell sharply after reporting a dramatic EPS growth slowdown and issuing weak 2026 guidance. Technical charts show potential support at $36.80 and $29, levels last seen between 2018 and 2020.
1. Decline Drivers
Novo Nordisk’s latest earnings revealed a sharp deceleration in EPS growth and conservative revenue guidance for 2026, triggering investor concern and a significant share price drop.
2. Technical Support Levels
Chart analysis identifies two key support zones at $36.80 and $29, which correspond to price floors established during 2018–2020 trading ranges.
3. Historical Context
The stock had enjoyed sustained growth above these levels over the past five years, driven by blockbuster obesity and diabetes drugs, making the current pullback notable.
4. Investor Implications
If the $36.80 level fails, a slide toward $29 could follow, but a hold at these supports may attract buyers eyeing value after the recent sell-off.